Assessment of depression symptoms in female cancer patients: focus on concurrent validity

Acta Biomed. 2020 Mar 13;91(2-S):16-18. doi: 10.23750/abm.v91i2-S.9285.

Abstract

Background and aim of the work: The present research explores Concurrent Validity of two depression measures the Beck Depression Inventory (BDI) and the Depression Subscale of the Hospital Anxiety and Depression Scale (HADS- Depression subscale) in specific oncological groups (female cancer and onco-hematological patients).

Method: A correlational study was designed and took place at Careggi Universitary Hospital in Florence, including 339 oncological patients, in particular 103 (59 Women and 44 men) patients suffering from lymphoma, and 236 patients suffering from female cancer. We estimated, by Pearson's r, Concurrent Validity between BDI and HADS depression's subscale.

Results: Correlations failed to reach the 0.55 cut-off in the female cancer group (r=.34, p<.001) but not in the onco-hematological patients (r= 0.56, p<.001).

Conclusion: The results stressing the need to develop and validate assessing tools that are specifically devoted to different groups of oncological patients. (www.actabiomedica.it).

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Cancer Survivors / psychology*
  • Depression / diagnosis*
  • Female
  • Humans
  • Lymphoma / psychology
  • Male
  • Middle Aged
  • Neoplasms / psychology*
  • Psychiatric Status Rating Scales*
  • Reproducibility of Results
  • Symptom Assessment / methods*
  • Women / psychology*